Previous 10 | Next 10 |
Global Blood Therapeutics reports Q4 earnings, summarizes upcoming catalysts Global Blood Therapeutics' ( GBT ) novel sickle cell disease drug, Oxbryta , has officially hit the market, netting a mere $2M in revenue. Meanwhile, R&D costs have nearly doubled in the last year. SG&A...
Newly created GBT Community Fund to provide $150,000 in grants to U.S. non-profits addressing the needs of the sickle cell disease community Donation of $100,000 to the Sickle Cell Disease Association of America to provide immediate support to those living with sickle cell disease ...
SOUTH SAN FRANCISCO, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), which is focused on transforming the treatment and care of people living with sickle cell disease, today announced steps the company is taking to support public health effort...
Introduction Syros ( SYRS ) is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases. Its leading drug is SY-1425, a selective retinoic acid receptor alpha agonist, or RARα ago...
Thesis Summary Global Blood Therapeutics Inc ( GBT ) has recently begun commercializing Oxbryta (Voxelotor). The drug is used in treating Sickle Cell Disease ( SCD ). While there is not much sales data to go on yet, given the results of the clinical trial and positive feedback from physician...
Last week, the stock market experienced its worst week since the financial crash of 2008 . And while the current week started on a more positive note, uncertainty will remain as long as the COVID-19 epidemic persists. With COVID-19 showing up in more and more countries outside of China -- and t...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Global Blood Therapeutics, Inc. (GBT) Q4 2019 Earnings Conference Call February 26, 2020 4:30 PM ET Company Participants Stephanie Yao - Senior Director of Investor Relations & Corporate Communications Ted Love - President & Chief Executive Officer Jeff Farrow - Chief Fin...
Global Blood Therapeutics (NASDAQ: GBT ): Q4 GAAP EPS of -$1.59 misses by $0.34 . More news on: Global Blood Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Obtained FDA approval of Oxbryta ® (voxelotor), the first treatment that specifically targets the root cause of sickle cell disease (SCD), three months ahead of schedule Made Oxbryta available to adults and children 12 years of age and older with SCD within days of FDA approval ...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...